Page last updated: 2024-11-07

candoxatril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

candoxatril : The 2,3-dihydro-1H-inden-5-yl ester of the active enantiomer of candoxatrilat. Candoxatril is an orally active prodrug of candoxatrilat, a potent neutral endopeptidase (NEP, neprilysin) inhibitor used in the treatment of chronic heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5362417
CHEMBL ID35084
CHEBI ID3353
SCHEMBL ID121666
SCHEMBL ID1649937
MeSH IDM0173582

Synonyms (44)

Synonym
CHEBI:3353 ,
cis-4-{[(1-{(2s)-3-(2,3-dihydro-1h-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid
4-({1-[(s)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid
DB00616
[4(s)-cis]-4-[[[1-[3-[(2,3-dihydro-1h-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid
candoxatril
D01070
candoxatril (jan/usan/inn)
123122-55-4
uk-79,300
4-[[1-[(2s)-3-(2,3-dihydro-1h-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
NCGC00248052-01
cas-123122-55-4
dtxsid6047286 ,
dtxcid4027286
NCGC00254350-01
tox21_300450
CHEMBL35084
uk-79300
(alphas)-1-((cis-4-carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid, alpha-5-indanyl ester
acp75508ee ,
candoxatril [usan:inn:ban]
unii-acp75508ee
cyclohexanecarboxylic acid, 4-(((1-(3-((2,3-dihydro-1h-inden-5-yl)oxy)-2-((2-methoxyethoxy)methyl)-3-oxopropyl)cyclopentyl)carbonyl)amino)-, (4(s)-cis)-
candoxatril [inn]
candoxatril [mi]
cis-4-(1-(2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)propyl)-1-cyclopentanecarboxamido)-1-cyclohexanecarboxylic acid l-
(alphas)-1-[(cis-4-carboxycyclohexyl)carbamoyl]-alpha-[(2-methoxyethoxy)methyl]cyclopentanepropionic acid, alpha-5-indanyl ester
candoxatril [jan]
candoxatril [usan]
candoxatril [mart.]
gtpl6492
SCHEMBL121666
SCHEMBL1649937
AKOS027326617
(s)-cis-4-{1 -[2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)-propyl]-1-cyclopentanecarboxamido}-1-cyclohexanecarboxylic acid
ZTWZVMIYIIVABD-OEMFJLHTSA-N
(s)-cis-4-{1 -[2-(5-indanyloxycarbonyl)-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxamido}-1-cyclohexanecarboxylic acid
HY-19649
CS-0016160
Q5032033
uk 79300 pound>> uk-79300 pound>> uk79300
BCP28764
cyclohexanecarboxylic acid, 4-[[[1-[(2s)-3-[(2,3-dihydro-1h-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-, cis-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma clearance of candoxatril was too rapid to enable pharmacokinetic parameter calculation in mouse and rabbit; for man, the apparent oral clearance was 57."( Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril.
Brearley, CJ; Cussans, NJ; Herron, M; Humphrey, MJ; Kaye, B; Mollatt, AR, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" An incremental dose-response effect was observed on the mean maximum observed plasma concentration (Cmax) of the active metabolite candoxatrilat (107."( Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure.
Allen, MJ; Johnson, HF; Lang, CC; Motwani, JG; Struthers, AD, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency45.91740.001628.015177.1139AID1224843; AID1224895
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency5.48290.154917.870243.6557AID1346877; AID1346891
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.74710.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.64)18.7374
1990's40 (65.57)18.2507
2000's13 (21.31)29.6817
2010's7 (11.48)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (46.77%)5.53%
Reviews4 (6.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (46.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]